Australian Clinical-Stage Drug Development Company Noxopharm (Asx:Nox) Has In-Licensed Novel Rna Technology Developed By Hudson Institute Of Medical Research. The Exclusive Global Contract Aims To Maximize Opportunities In Rna Drug Discovery And Mrna Vaccine Manufacture Through Noxopharm
